Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

58
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
58
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

67
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
67
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

2.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same author

Endothelial-immune cells-on-chip for multiplex evaluation of drug responses through patient plasma screening.

Stem cell research & therapy·2026
Same author

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.

Nature communications·2026
Same author

Understanding the workplace needs of autistic adults in Singapore: insights to inform inclusive AI support.

Frontiers in psychiatry·2026
Same author

Isolation of small extracellular vesicles from small volumes of blood plasma using size exclusion chromatography and density gradient ultracentrifugation.

eLife·2026
Same author

The oral-gut microbiome axis in diabetes mellitus: a systematic review and emerging clinical perspectives.

Diabetes research and clinical practice·2026

Related Experiment Video

Updated: May 7, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.5K

Pituitary apoplexy associated with cabergoline therapy.

Edwin Chng1, Rinkoo Dalan

  • 1Department of Endocrinology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|October 12, 2013
PubMed
Summary

Pituitary apoplexy, a rare emergency, can be a risk during dopamine agonist treatment for prolactinoma. This case highlights a patient who recovered well with conservative care after developing this condition during cabergoline therapy.

Keywords:
BromocriptineCabergolineDopamine agonistPituitary apoplexyProlactinoma

More Related Videos

Induction of Cerebral Arterial Gas Embolism in Rat
06:26

Induction of Cerebral Arterial Gas Embolism in Rat

Published on: October 18, 2024

1.0K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

1.3K

Related Experiment Videos

Last Updated: May 7, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

18.5K
Induction of Cerebral Arterial Gas Embolism in Rat
06:26

Induction of Cerebral Arterial Gas Embolism in Rat

Published on: October 18, 2024

1.0K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

1.3K

Area of Science:

  • Endocrinology
  • Neuroscience

Background:

  • Pituitary apoplexy is a rare but serious condition involving pituitary gland hemorrhage or infarction.
  • Dopamine agonists, particularly bromocriptine, are recognized predisposing factors for pituitary apoplexy.
  • Prolactinoma is a common pituitary tumor often treated with dopamine agonists.

Observation:

  • A 20-year-old Chinese male with prolactinoma developed pituitary apoplexy.
  • The event occurred 6 weeks after initiating cabergoline treatment.
  • The patient was managed conservatively with supportive therapy.

Findings:

  • The patient experienced a full recovery without any loss of pituitary function.
  • This case adds to the literature on pituitary apoplexy associated with dopamine agonist therapy.
  • A review of similar cases provides further insights into this rare complication.

Implications:

  • Conservative management can be effective for pituitary apoplexy in select cases.
  • Clinicians should be aware of the potential risk of pituitary apoplexy when prescribing dopamine agonists for prolactinoma.
  • Further research may elucidate specific risk factors and optimal management strategies for dopamine agonist-induced pituitary apoplexy.